IASLC 2021 Hot Topic Meeting: Small Cell Lung Cancer

SCLC 2021 Image
Overview

The fourth biennial IASLC Small Cell Lung Cancer Meeting will be held as a Worldwide Virtual Event in the Fall of 2021. The meeting will focus on preclinical and clinical advances in small cell lung cancer (SCLC) research, including, but not limited to, basic research on oncogenesis and biology of disease, preclinical therapeutic research, and highlights of ongoing clinical translation. From its inception, this meeting's goals have been to provide a “state-of-the-state” update on recent progress in small cell lung cancer research, to establish a forward-looking perspective on key unanswered questions in the field, and to promote research collaboration among small cell lung cancer investigators. We hope that you will join us for #SCLC21. Additional meeting information will follow soon.

Related Files
Date
Oct 29, 2021 -
Oct 30, 2021

Detailed Program

Thursday, October 28, 2021 

RSVP Today 

Learn More

CURE® is proud to host the second annual Lung Cancer Heroes® recognition event on Thursday, October 28, 2021 at 6:30 p.m. ET! Join us in honoring and expressing our heartfelt gratitude to this year’s honorees who have made a difference in the lung cancer community and continue to bring hope and healing to patients and their loved ones. CURE® is also pleased to announce that award-winning actress and filmmaker Laura Dern will be delivering this year’s keynote address! Please join us to make it an evening to remember.

Lung Cancer Heros Keynote Speaker Laura Dern Thursday October, 28 2021

 

 

 

 

Friday, October 29, 2021 

All Times in ET

Opening Ceremony and Keynote 

Presentation 

Start Time

Presenter 

Chairs' Welcome Address  11:00 Charles Rudin and Triparna Sen, Meeting Chairs 
IASLC President Welcome 11:05  Heather Wakelee 
IASLC Membership: Why We Should All be IASLC Members  11:08 Katie Maher
Remembrance for Pierre Massion 11:11   Johathan Lehman
Keynote: Lessons from CDX models in SCLC 11:15 Caroline Dive 
Keynote Discussion with Q+A 11:44  

 

All Times in ET

Single Cell Analysis in SCLC 

Presentation  Start Time Presenter
Session Welcome   Caroline Dive, Session Moderator 
Signatures of Plasticity, Metastasis, and Immunosuppression in a Single-cell Atlas of Human Small Cell Lung Cancer 12:10 Joseph Chan
Plasticity of SCLC Subtypes: Lessons from GEMMs   12:22 Trudy Oliver 
Translating SCLC Molecular Subtypes into Clinical Practice: Opportunities for Precision Medicine and the Challenge of Plasticity 12:35 Lauren Byers
Single Cell Mass Cytometry and SCLC 12:47 Jonathan Lehman 
Panel Discussion with Q&A 13:00  

All Times in ET

Omics in SCLC

Presentation Start Time Presenter
Session Welcome   Trudy Oliver, Session Moderator
Genomic Characterization of SCLC  13:20 Julie George
Systematic Determination of Functional Impacts of Recurrent SCLC Mutations  13:32 Dominic Rothwell 
Recurrent WNT Pathway Alterations are Frequent in Relapsed Small-cell Lung Cancer 13:44 Siddhartha Devarakonda
Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation 13:56 Triparna Sen 
Panel Discussion with Q&A 14:08  

All Times in ET

Biomarkers/Liquid Biopsy/Metastasis in SCLC

Presentation  Start Time Presenter 
Session Welcome    Christine Lovly 
Small-cell Lung Cancer Brain Metastases Transcriptomics  14:30 Ata Abbas
Neddylation Inhibition as a Therapeutic Vulnerability in SCLC  14:44 David MacPherson 
Molecular Profiling and Phenotype Mapping of SCLC Using Patient-derived Organoids  14:58 Hiroyuki Yasuda 
SLFN11 in SCLC 15:10 Yves Pommier
Panel Discussion with Q&A  15:23  

All Times in ET

Novel Pathways and Targets in SCLC- Session 1

Presentation  Start Time Presenter
Session Welcome    Lauren Byers, Session Moderator 
Immunogenic Radiosensitization of SCLC with DNA Repair Inhibitors 15:40 Ben Lok 
DLL3 15:52 Katie Tully
LSD1-ZFP63L1 in SCLC 16:04 Matt Oser 
Interactions between SCLC and Neurons  16:16 Humsa Venkatesh
Panel Discussion with Q&A 16:28  

All Times in ET

Clinical Trials in SCLC 

Presentation  Start Time Presenter
Session Welcome   Kristin Higgins, Session Moderator 
Phase I/II Study of Olaparib and Temozolomide in SCLC: Updated Analysis 16:50 Catherine Meador  
Clinical Trials in SCLC Immunotherapy 17:03 Luis Paz-Ares
Inflamed Subtype of SCLC and its Clinical Implications  17:17 Taofeek Owonikoko
Panel Discussion with Q&A  17:30  

All Times in ET

Closing 

Presentation  Start Time Presenter
Day 1 Closing Message  17:46 Charles Rudin and Triparna Sen, Meeting Chairs 

All Times in ET

Satellite CME Symposium By PeerView:

Translating Science, Transforming Practice, and Making Headway Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next?

18:05 - 19:05 

Register for the Symposium 

Saturday, October 30, 2021 

All Times in ET

Early Career Session (October 30) 

Presentation  Start Time Presenter
Session Welcome    Ben Lok, Moderator
MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate   10:00 Abbie Ireland  
XPO1 as a Target for Chemoresistance in SCLC  10:11 Alvaro Quintanal Villalonga 
Profiling of the cfDNA methylome for Detection and Subtyping of Small Cell Lung Cancers 10:21  Francesca Chemi 
Targeting CDK7 to Enhance Immunity in SCLC 10:32 Hua Zhang 
To Be or Not to B7-H6: Advancing Immunotherapy in Small Cell Lung Cancer 10:44 Portia Thomas  
Molecular Subtyping of SCLC in Tumor Tissues and CTCs 10:52 Prasad Kopparapu 
Panel Discussion with Q&A  11:03  

All Times in ET

Welcome and Keynote 

Presentation  Start Time Presenter 
Welcome  11:30  Charles Rudin and Triparna Sen, Meeting Chair 
Keynote: Lessons from Mouse Models 11:35 Julien Sage
Keynote Discussion with Q&A 11:58  

All Times in ET

Subtypes/ Biomarkers in SCLC 

Presentation  Start Time Presenter
Session Welcome   Jane Johnson, Session Moderator

 Histological Subtyping of SCLC

12:10 Natasha Rekhtman

SCLC Subgroups and Their Potential Clinical Significance 

12:24

Carl Gay  

 Whole Genome Methylation Analysis of Extensive Stage SCLC Samples Reveals Distinct Subtype-Specific Patterns  12:34 Simon Heeke
SCLC Biomarkers for Lung Cancer Screening  12:47 Samir Hanash
Panel Discussion with Q&A 13:04  

All Times in ET

Novel Pathways and Targets in SCLC - Session 2 

Presentation  Start Time Presenter
Session Welcome   JT Poirier, Session Moderator 
Therapeutic Targeting of ATR Yields Durable Regressions in High Replication Stress SCLCs 13:20  Anish Thomas 
Molecular Subtypes of Primary SCLC Tumors and their Associations with Neuroendocrine and Therapeutic Markers 13:36 Haobin Chen
Guanosine Triphosphate Links MYC-dependent Metabolic and Ribosome Programs in Small-cell Lung Cancer 13:48  Ralph Deberardinis
Ferroptosis Response Segregates Small Cell Lung Cancer (SCLC) Neuroendocrine Subtypes 14:00  Silvia von Karstedt 
Panel Discussion with Q&A  14:12   

All Times in ET

Mouse Models (Xenografts and GEMMs)

Presentation  Start Time Presenter
Session Welcome    Roman Thomas, Session Moderator 

PBRM1 Functions as a Tumor Suppressor in Small Cell Lung Cancer

14:30  Arnaud Augert 
Chemoresistance and co Clinical Trials  14:43 Ben Drapkin & Marcello Stanzione 
Characterizing Chemoradiation Resistance in Small Cell Lung Cancer 14:56 Luigi Marchionni
Modeling Oncogenic & Histologic Transformation in the Lung 15:10 Eric Gardner
Panel Discussion with Q&A  15:24  

All Times in ET

 Immunotherapy Approaches in SCLC 

Presentation  Start Time Presenter 
Session Welcome   Ticiana Leal, Session Moderator 
EZH2 and Plasticity of the Immune Response in SCLC 15:40  David Barbie 
Harnessing the innate Immune System to Treat SCLC 15:53 Kate Sutherland
CDKs as Targets in Small Cell Lung Cancer  16:06 Kwok Kin Wong
Examining Predictors of Response to Immune Checkpoint Blockade in SCLC 16:17 Nitin Roper
Panel Discussion with Q&A  16:28   

All Times in ET

Day Two Closing 

Presentation  Start Time Presenter
Closing Message 16:50  Charles Rudin and Triparna Sen, Meeting Chairs

 

All Times in ET

 
Presentation Time
Industry Sponsored Symposium By Jazz Pharmaceuticals 17:05 - 18:20 

 

Thursday, October 28, 2021 

RSVP Today 

Learn More

CURE® is proud to host the second annual Lung Cancer Heroes® recognition event on Thursday, October 28, 2021 at 6:30 p.m. ET! Join us in honoring and expressing our heartfelt gratitude to this year’s honorees who have made a difference in the lung cancer community and continue to bring hope and healing to patients and their loved ones. CURE® is also pleased to announce that award-winning actress and filmmaker Laura Dern will be delivering this year’s keynote address! Please join us to make it an evening to remember.

Lung Cancer Heros Keynote Speaker Laura Dern Thursday October, 28 2021

 

 

 

 

Friday, October 29, 2021 

All Times in ET

Opening Ceremony and Keynote 

Presentation 

Start Time

Presenter 

Chairs' Welcome Address  11:00 Charles Rudin and Triparna Sen, Meeting Chairs 
IASLC President Welcome 11:05  Heather Wakelee 
IASLC Membership: Why We Should All be IASLC Members  11:08 Katie Maher
Remembrance for Pierre Massion 11:11   Johathan Lehman
Keynote: Lessons from CDX models in SCLC 11:15 Caroline Dive 
Keynote Discussion with Q+A 11:44  

 

All Times in ET

Single Cell Analysis in SCLC 

Presentation  Start Time Presenter
Session Welcome   Caroline Dive, Session Moderator 
Signatures of Plasticity, Metastasis, and Immunosuppression in a Single-cell Atlas of Human Small Cell Lung Cancer 12:10 Joseph Chan
Plasticity of SCLC Subtypes: Lessons from GEMMs   12:22 Trudy Oliver 
Translating SCLC Molecular Subtypes into Clinical Practice: Opportunities for Precision Medicine and the Challenge of Plasticity 12:35 Lauren Byers
Single Cell Mass Cytometry and SCLC 12:47 Jonathan Lehman 
Panel Discussion with Q&A 13:00  

All Times in ET

Omics in SCLC

Presentation Start Time Presenter
Session Welcome   Trudy Oliver, Session Moderator
Genomic Characterization of SCLC  13:20 Julie George
Systematic Determination of Functional Impacts of Recurrent SCLC Mutations  13:32 Dominic Rothwell 
Recurrent WNT Pathway Alterations are Frequent in Relapsed Small-cell Lung Cancer 13:44 Siddhartha Devarakonda
Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation 13:56 Triparna Sen 
Panel Discussion with Q&A 14:08  

All Times in ET

Biomarkers/Liquid Biopsy/Metastasis in SCLC

Presentation  Start Time Presenter 
Session Welcome    Christine Lovly 
Small-cell Lung Cancer Brain Metastases Transcriptomics  14:30 Ata Abbas
Neddylation Inhibition as a Therapeutic Vulnerability in SCLC  14:44 David MacPherson 
Molecular Profiling and Phenotype Mapping of SCLC Using Patient-derived Organoids  14:58 Hiroyuki Yasuda 
SLFN11 in SCLC 15:10 Yves Pommier
Panel Discussion with Q&A  15:23  

All Times in ET

Novel Pathways and Targets in SCLC- Session 1

Presentation  Start Time Presenter
Session Welcome    Lauren Byers, Session Moderator 
Immunogenic Radiosensitization of SCLC with DNA Repair Inhibitors 15:40 Ben Lok 
DLL3 15:52 Katie Tully
LSD1-ZFP63L1 in SCLC 16:04 Matt Oser 
Interactions between SCLC and Neurons  16:16 Humsa Venkatesh
Panel Discussion with Q&A 16:28  

All Times in ET

Clinical Trials in SCLC 

Presentation  Start Time Presenter
Session Welcome   Kristin Higgins, Session Moderator 
Phase I/II Study of Olaparib and Temozolomide in SCLC: Updated Analysis 16:50 Catherine Meador  
Clinical Trials in SCLC Immunotherapy 17:03 Luis Paz-Ares
Inflamed Subtype of SCLC and its Clinical Implications  17:17 Taofeek Owonikoko
Panel Discussion with Q&A  17:30  

All Times in ET

Closing 

Presentation  Start Time Presenter
Day 1 Closing Message  17:46 Charles Rudin and Triparna Sen, Meeting Chairs 

All Times in ET

Satellite CME Symposium By PeerView:

Translating Science, Transforming Practice, and Making Headway Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next?

18:05 - 19:05 

Register for the Symposium 

Saturday, October 30, 2021 

All Times in ET

Early Career Session (October 30) 

Presentation  Start Time Presenter
Session Welcome    Ben Lok, Moderator
MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate   10:00 Abbie Ireland  
XPO1 as a Target for Chemoresistance in SCLC  10:11 Alvaro Quintanal Villalonga 
Profiling of the cfDNA methylome for Detection and Subtyping of Small Cell Lung Cancers 10:21  Francesca Chemi 
Targeting CDK7 to Enhance Immunity in SCLC 10:32 Hua Zhang 
To Be or Not to B7-H6: Advancing Immunotherapy in Small Cell Lung Cancer 10:44 Portia Thomas  
Molecular Subtyping of SCLC in Tumor Tissues and CTCs 10:52 Prasad Kopparapu 
Panel Discussion with Q&A  11:03  

All Times in ET

Welcome and Keynote 

Presentation  Start Time Presenter 
Welcome  11:30  Charles Rudin and Triparna Sen, Meeting Chair 
Keynote: Lessons from Mouse Models 11:35 Julien Sage
Keynote Discussion with Q&A 11:58  

All Times in ET

Subtypes/ Biomarkers in SCLC 

Presentation  Start Time Presenter
Session Welcome   Jane Johnson, Session Moderator

 Histological Subtyping of SCLC

12:10 Natasha Rekhtman

SCLC Subgroups and Their Potential Clinical Significance 

12:24

Carl Gay  

 Whole Genome Methylation Analysis of Extensive Stage SCLC Samples Reveals Distinct Subtype-Specific Patterns  12:34 Simon Heeke
SCLC Biomarkers for Lung Cancer Screening  12:47 Samir Hanash
Panel Discussion with Q&A 13:04  

All Times in ET

Novel Pathways and Targets in SCLC - Session 2 

Presentation  Start Time Presenter
Session Welcome   JT Poirier, Session Moderator 
Therapeutic Targeting of ATR Yields Durable Regressions in High Replication Stress SCLCs 13:20  Anish Thomas 
Molecular Subtypes of Primary SCLC Tumors and their Associations with Neuroendocrine and Therapeutic Markers 13:36 Haobin Chen
Guanosine Triphosphate Links MYC-dependent Metabolic and Ribosome Programs in Small-cell Lung Cancer 13:48  Ralph Deberardinis
Ferroptosis Response Segregates Small Cell Lung Cancer (SCLC) Neuroendocrine Subtypes 14:00  Silvia von Karstedt 
Panel Discussion with Q&A  14:12   

All Times in ET

Mouse Models (Xenografts and GEMMs)

Presentation  Start Time Presenter
Session Welcome    Roman Thomas, Session Moderator 

PBRM1 Functions as a Tumor Suppressor in Small Cell Lung Cancer

14:30  Arnaud Augert 
Chemoresistance and co Clinical Trials  14:43 Ben Drapkin & Marcello Stanzione 
Characterizing Chemoradiation Resistance in Small Cell Lung Cancer 14:56 Luigi Marchionni
Modeling Oncogenic & Histologic Transformation in the Lung 15:10 Eric Gardner
Panel Discussion with Q&A  15:24  

All Times in ET

 Immunotherapy Approaches in SCLC 

Presentation  Start Time Presenter 
Session Welcome   Ticiana Leal, Session Moderator 
EZH2 and Plasticity of the Immune Response in SCLC 15:40  David Barbie 
Harnessing the innate Immune System to Treat SCLC 15:53 Kate Sutherland
CDKs as Targets in Small Cell Lung Cancer  16:06 Kwok Kin Wong
Examining Predictors of Response to Immune Checkpoint Blockade in SCLC 16:17 Nitin Roper
Panel Discussion with Q&A  16:28   

All Times in ET

Day Two Closing 

Presentation  Start Time Presenter
Closing Message 16:50  Charles Rudin and Triparna Sen, Meeting Chairs

 

All Times in ET

 
Presentation Time
Industry Sponsored Symposium By Jazz Pharmaceuticals 17:05 - 18:20 

 

Message from Meeting Chair, Dr. Triparna Sen

Dr. Triparna Sen shares why you should join us for this year's IASLC Hot Topic Meeting: Small Cell Lung Cancer. From highlights on ongoing clinical trials to novel technologies in SCLC, it does not matter what area of SCLC research or treatment you are in, you will surely find a session that aligns to your discipline in the program. 

Follow Us on Twitter

Share

Meeting Chairs

Triparna Sen
Triparna Sen

PhD

Assistant Attending in the Department of Medicine
Memorial Sloan Kettering Cancer Center
Headshot of Dr. Rudin
Charles M. Rudin

MD, PhD

Medical Oncologist
Memorial Sloan Kettering

Interested in advertising and exhibit opportunities?